作者： admin

Medical researchers from Shanghai Jiao Tong University School of Medicine have achieved a revolutionary breakthrough in treating triple-negative breast cancer, one of the most aggressive forms of the disease. The team at Ruijin Hospital presented their landmark findings at the prestigious San Antonio Breast Cancer Symposium in December, revealing a new therapeutic protocol that dramatically improves patient outcomes.

The comprehensive nationwide study, initiated in 2015, involved 786 patients across 19 medical centers and demonstrated unprecedented success rates. The innovative approach, which integrates carboplatin into standard adjuvant chemotherapy regimens, reduced postoperative recurrence risk by 34% and mortality by an remarkable 61%. The three-year disease-free survival rate reached 93.1%, while distant metastasis-free survival achieved 95.2% and overall survival climbed to 98.3%.

International oncology experts have hailed the Chinese research as a transformative advancement in breast cancer treatment. The study addresses particularly challenging aspects of triple-negative breast cancer, which has historically lacked effective therapeutic targets and carried high risks of recurrence and metastasis. The protocol’s applicability to most operable patients positions it as a potential new standard of care.

The research team emphasized that their findings provide robust clinical evidence that could reshape global treatment guidelines and offer new hope for patients worldwide facing this formidable cancer subtype. The medical community anticipates that these results will influence international practice standards and significantly improve survival prospects for thousands of patients annually.

In a significant development for healthcare accessibility, Beijing Tongren Hospital has issued its first prescription for Sycume, a breakthrough thyroid eye disease medication newly incorporated into China’s National Drug Reimbursement List. This milestone follows the January 1st implementation of the updated list, which introduces 114 new pharmaceutical coverages including 50 pioneering innovative medicines, expanding total covered medications to 3,253 formulations nationwide.

Sycume, developed by Shanghai-based Innovent Biologics, represents a therapeutic advancement for patients experiencing moderate to severe thyroid eye disease. The injectable treatment specifically addresses distressing symptoms including proptosis (eye bulging), orbital inflammation, and diplopia (double vision). Having received Chinese market approval in March, the drug’s inclusion in the reimbursement program substantially enhances treatment accessibility.

Professor Li Dongmei of Beijing Tongren Hospital emphasized the transformative financial impact of this policy change. The per-dose price has dramatically decreased from approximately 15,000 yuan ($2,148) to under 6,000 yuan following reimbursement list inclusion. With insurance coverage, patients now experience approximately 10,000 yuan in savings per treatment cycle compared to previous out-of-pocket expenses.

This strategic expansion of China’s drug reimbursement framework, administered by the National Healthcare Security Administration, not only alleviates economic burdens but also ensures broader patient access to effective and safe therapeutic interventions. The policy shift demonstrates China’s ongoing commitment to enhancing healthcare affordability while supporting innovative medical treatments for complex conditions.